Company: RGNX
Filing Date: 2025-04-08
Form Type: DEF 14A
Source: 0000950170-25-052069
Chunk: 42

Company: REGENXBIO Inc.
Filing Date: 2025-04-08
Form: DEF 14A
Chunk 42
---
 that the engagement did not raise any conflict of interest. Peer Group Data . Our Compensation Committee reviews our peer group annually to ensure it remains relevant and current. Our Compensation Committee, upon advice received from its independent compensation consultant, selected the 15 companies that comprised our peer group for determining 2024 compensation through a screening process that considered publicly traded biopharmaceutical companies similar to us in headcount and market capitalization. Our 2024 peer group companies were as follows:

| 2seventy bio, Inc.              | Denali Therapeutics Inc.     | PTC Therapeutics, Inc.         |
| Agios Pharmaceuticals, Inc.     | Editas Medicine, Inc.        | Sangamo Therapeutics, Inc.     |
| bluebird bio, Inc.(1)           | MacroGenics, Inc.            | Supernus Pharmaceuticals, Inc. |
| Blueprint Medicines Corporation | MeiraGTx Holdings plc        | Ultragenyx Pharmaceutical Inc. |
| CRISPR Therapeutics AG          | Mirati Therapeutics, Inc.(2) | uniQure N.V.                   |

(1) In February 2025 bluebird bio, Inc. announced a definitive agreement to be acquired. (2) In January 2024 Mirati Therapeutics, Inc. was acquired by Bristol Myers Squibb. Survey Data . In addition to using peer group data, the Compensation Committee references survey data for comparable companies from the Radford Global Life Sciences Survey to inform compensation decisions.

<div align='center'>30</div>

Elements of Compensation Compensation packages for our NEOs in 2024 included the following elements:

| Element                                  | Purpose of Element                                                                                                                                                                     |
| Base salary                              | Provide NEOs with a market competitive salary that recognizes experience, value and level of contribution to achieving the Company’s objectives                                        |
| Annual short-term cash incentive         | Motivate and reward NEOs for short-term individual and corporate performanceAttract and retain talented NEOs                                                                           |
| Long-term equity incentives              | Motivate and reward NEOs for long-term corporate performanceAlign the interests of NEOs and stockholders, thereby enhancing stockholder valueAttract and retain talented NEOs          |
| Health, welfare and retirement benefits  | Provide competitive benefits to protect employees’ and their covered dependents’ health and welfare, and to foster retirement savings                                                  |
| Severance and change in control benefits | Discourage turnover and allow NEOs to respond to the possibility of a change in control without being influenced by the potential effects of a change in